

Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis

Stephen H Little, Kwan-Leung Chan, Ian G Burwash

Heart 2007;93:848–855. doi: 10.1136/hrt.2006.098392

See end of article for authors' affiliations

Correspondence to:
Dr I G Burwash, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada K1Y 4W7; iburwash@ottawaheart.ca

Accepted
19 September 2006
Published Online First
28 November 2006

Transvalvular pressure gradient and aortic valve area (AVA) are the standard indices to determine the haemodynamic severity of aortic stenosis (AS).^{1,2} However, a patient's physiological state can affect these indices and therefore the assessment of AS severity. Pressure gradients and AVA vary with transvalvular flow and flow-mediated forces.^{3–10} Valve resistance, % left ventricular stroke work loss (% LVSW loss) and the energy loss coefficient (ELCo) have been proposed as alternative indices of AS severity that may be less sensitive to transvalvular flow.^{7,11–21} However, this has not been corroborated in individual patients when transvalvular flow was altered using exercise or inotropic infusion.^{6,9}

The impact of blood pressure (BP) on the assessment of AS severity has received less attention.² Traditionally, low systolic BP (SBP) and a decreased pulse pressure have been considered signs of severe AS, whereas the presence of hypertension excluded severe AS.²² However, recent data demonstrate that hypertension commonly coexists with and is a risk factor for AS.^{23–27} Hypertension can lead to an underestimation of AS severity on physical examination.²² Furthermore, BP and systemic vascular resistance may influence the assessment of the haemodynamic severity.² In a catheterisation study, Laskey *et al*²⁸ observed a decrease in transvalvular pressure gradient and a potential underestimation of AS severity when peripheral resistance was increased. Similarly, induction of hypertension in an animal model of supravalvular AS resulted in a decrease in pressure gradient and an increase in the area of the supravalvular stenosis.²⁹ In contrast, pressure gradient increased and valve area decreased when systemic vascular resistance was increased in an *in vitro* model of AS, leading to a potential overestimation of the AS severity.³⁰ AS and hypertension commonly coexist in our ageing population, and the interaction of systemic BP with the evaluation of AS severity

Objective: To investigate the impact of blood pressure (BP) on the Doppler echocardiographic (Doppler-echo) evaluation of severity of aortic stenosis (AS).

Methods: Handgrip exercise or phenylephrine infusion was used to increase BP in 22 patients with AS. Indices of AS severity (mean pressure gradient (ΔP_{mean}), aortic valve area (AVA), valve resistance, percentage left ventricular stroke work loss (% LVSW loss) and the energy loss coefficient (ELCo) were measured at baseline, peak BP intervention and recovery.

Results: From baseline to peak intervention, mean (SD) BP increased (99 (8) vs 121 (10) mm Hg, $p < 0.001$), systemic vascular resistance (SVR) increased (1294 (264) vs 1552 (372) dyne \times s/cm⁵, $p < 0.001$) and mean (SD) transvalvular flow rate (Q_{mean}) decreased (323 (67) vs 306 (66) ml/s, $p = 0.02$). There was no change in ΔP_{mean} (36 (13) vs 36 (14) mm Hg, $p = \text{NS}$). However, there was a decrease in AVA (1.15 (0.32) vs 1.09 (0.33) cm², $p = 0.02$) and ELCo (1.32 (0.40) vs 1.24 (0.42) cm², $p = 0.04$), and an increase in valve resistance (153 (63) vs 164 (74) dyne \times s/cm⁵, $p = 0.02$), suggesting a more severe valve stenosis. In contrast, % LVSW loss decreased (19.8 (6) vs 16.5 (6)%, $p < 0.001$), suggesting a less severe valve stenosis. There was an inverse relationship between the change in mean BP and AVA ($r = -0.34$, $p = 0.02$); however, only the change in Q_{mean} was an independent predictor of the change in AVA ($r = 0.81$, $p < 0.001$).

Conclusions: Acute BP elevation due to increased SVR can affect the Doppler-echo evaluation of AS severity. However, the impact of BP on the assessment of AS severity depends primarily on the associated change in Q_{mean} , rather than on an independent effect of SVR or arterial compliance, and can result in a valve appearing either more or less stenotic depending on the direction and magnitude of the change in Q_{mean} .

needs to be better understood to manage patients optimally.^{31,32} The purpose of this study was to investigate the effects of systemic BP on the assessment of AS severity using Doppler echocardiography (Doppler-echo) in patients with valvular AS.

METHODS

Study population

This was a transversal study of 22 patients with isolated valvular AS (aortic and mitral regurgitation $\leq 1+$) who underwent echocardiography at the University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Patients were enrolled if they were ≥ 18 years of age, in sinus rhythm and had an abnormal aortic valve with a transvalvular velocity ≥ 2.5 m/s. Patients were excluded if they had severe hypertension ($> 180/110$ mm Hg), recent acute coronary syndrome or cerebrovascular accident (during the past 6 months), Canadian Cardiovascular Society class III–IV angina pectoris, New York Heart Association class III–IV congestive heart failure, severe left ventricular dysfunction (ejection fraction (EF) $< 30\%$) or symptomatic peripheral vascular disease. The study was approved by the institutional review board and all subjects gave written informed consent.

Abbreviations: AS, aortic stenosis; AVA, aortic valve area; BP, blood pressure; CO, cardiac output; Doppler-echo, Doppler echocardiography; EF, ejection fraction; ELCo, energy loss coefficient; LV, left ventricular; LVOT, left ventricular outflow tract; % LVSW loss, percentage left ventricular stroke work loss; ΔP_{max} , maximum transvalvular pressure gradient; ΔP_{mean} , mean transvalvular pressure gradient; Q_{mean} , mean transvalvular flow rate; SAC, systemic arterial compliance; SBP, systolic blood pressure; SV, stroke volume; SVR, systemic vascular resistance

Study protocol

Baseline supine brachial BP was measured in the non-dominant arm using a mercury sphygmomanometer after 5 min of rest. Each patient underwent a baseline resting Doppler-echo examination. Echocardiographic data were stored on high-density magneto-optical disks for later off-line analysis.

Left ventricular outflow tract (LVOT) diameter was obtained using two-dimensional echocardiography, LVOT velocity using pulsed-wave Doppler and transvalvular velocity using continuous wave Doppler, as described previously.⁹ The ascending aorta diameter was measured at the sinotubular junction in the parasternal long-axis view. Left ventricular (LV) volumes were derived by the biplane method of discs.

Following the baseline examination, patients underwent a BP intervention protocol using either handgrip exercise or phenylephrine infusion.

Handgrip protocol

Patients were instructed to use their dominant hand to perform rhythmic handgrip exercise (30 contractions/min) at 40% of their maximum voluntary contraction using a calibrated dynamometer. Handgrip exercise was performed for 8 min, with acquisition of Doppler-echo and BP measurements during the final 2 min. Doppler-echo and BP measurements were repeated in recovery after 5 min of rest.

Phenylephrine protocol

Patients underwent a graded intravenous phenylephrine infusion protocol as described previously from our institution (University of Ottawa Heart Institute, Ontario, Canada).³³ The phenylephrine infusion was started at 0.4 µg/kg/min and increased to 0.8, 1.6 and 2.4 µg/kg/min at 6 min intervals. The infusion was discontinued if SBP increased >40 mm Hg, diastolic BP increased >20 mm Hg, or the patient developed intolerable symptoms or ventricular arrhythmias. Doppler-echo and BP data were acquired in the last 2 min of the final infusion rate. Doppler-echo and BP data were repeated in recovery 20 min after discontinuation of the phenylephrine infusion.

Doppler-echo haemodynamic analysis

Doppler-echo measurements were averaged from 3 to 5 cardiac cycles. LVOT area (CSA_{LVOT}) was calculated from the diameter using a circular assumption. Stroke volume was calculated from the LVOT and transvalvular velocity time integrals (VTI_{LVOT} , VTI_{AS}), as³⁴:

$$SV = VTI_{LVOT} \times CSA_{LVOT}$$

Mean transvalvular flow rate (Q_{mean}) was derived by dividing stroke volume by the systolic ejection time, and cardiac output (CO) by multiplying stroke volume and heart rate. Systemic vascular resistance (SVR) was estimated as:

$$SVR = 80 \times (\text{mean BP}) / CO$$

where mean BP was obtained using a mercury sphygmomanometer. Systemic arterial compliance (SAC) was calculated as³⁵:

$$SAC = SV / (SBP - DBP)$$

where SBP and DBP are the systolic and diastolic BPs.

Doppler-echo indices of AS severity

Peak transvalvular pressure gradient (ΔP_{max}) was calculated using the peak transvalvular (V_{max}) and LVOT velocity (V_{LVOT}), and the modified Bernoulli equation³⁴:

$$\Delta P_{max} = 4 \times (V_{max}^2 - V_{LVOT}^2)$$

Mean transvalvular pressure gradient (ΔP_{mean}) was obtained by averaging instantaneous pressure gradients over the ejection period. AVA was calculated by continuity equation,^{5 36 37} where:

$$AVA = (VTI_{LVOT} / VTI_{AS}) \times CSA_{LVOT}$$

Valve resistance was calculated as³⁸:

$$\text{Resistance} = (\Delta P_{mean} / Q_{mean}) \times 1333$$

% LVSW loss was derived as^{9 19 20}:

$$\% \text{ LVSW loss} = (\Delta P_{mean} / LVP_{mean}) \times 100\%$$

where LVP_{mean} is the mean systolic left ventricular pressure, calculated by adding the SBP and ΔP_{mean} .

The ELCo was calculated as²¹:

$$ELCo = (AVA \times Ao) / (Ao - AVA)$$

where Ao is the ascending aorta area.

Statistical analysis

Data are expressed as mean (SD). Differences between indices of AS severity at baseline, BP intervention and recovery were assessed by analysis of variance with repeated measures. The relationships between the change in indices of AS severity and the change in haemodynamic variables were compared using least-squares linear regression analysis. Correlations were described by Pearson's correlation coefficient. Stepwise linear regression analysis was used to identify haemodynamic variables on univariate analysis that were independent predictors of the change in an index of AS severity. A p value ≤ 0.05 was considered significant.

RESULTS

Patient characteristics

Table 1 shows the demographic and baseline Doppler-echo data in the 22 patients. In all, 16 (72%) patients had hypertension and 4 (18%) patients had symptomatic coronary artery disease. The aetiology of AS was degenerative (trileaflet) in 11 patients, bicuspid aortic valve disease in 10 patients and indeterminate in 1 patient. Baseline ΔP_{mean} (SD) was 36 (12) mm Hg (17–62 mm Hg) and AVA was 1.15 (0.32) cm^2 (0.72–1.82 cm^2).

Haemodynamic changes during BP intervention

BP was altered by exercise handgrip in 18 patients and by phenylephrine infusion in 4 patients. There were no adverse events in the exercise handgrip cohort, and all patients completed the protocol. Two patients undergoing phenylephrine infusion reported minor symptoms of flushing at 1.6 µg/kg/

Table 1 Demographic and baseline echocardiographic characteristics of the total cohort (n = 22)

Variable	Mean (SD)
Clinical characteristics	
Age (years)	70 (10)
Gender (M:F)	16:6
BSA (cm^2)	1.96 (0.21)
Haemodynamic variables	
Heart rate (bpm)	62 (8)
BP (mm Hg)	143 (14)/77 (9)
Stroke volume (ml)	104 (19)
Q_{mean} (ml/s)	323 (67)
LV EF (%)	73 (8)
Stenotic indices	
ΔP_{mean} (mm Hg)	36 (13)
AVA (cm^2)	1.15 (0.32)
Resistance ($dyne \times s / cm^5$)	153 (63)
% LVSW loss (%)	19.8 (6.3)
ELCo (cm^2)	1.32 (0.4)
AS severity (based on AVA)	4:10:8
Mild: moderate: severe	

AS, aortic stenosis; AVA, aortic valve area; BP, blood pressure; BSA, body surface area; EF, ejection fraction; ELCo, energy loss coefficient; LV, left ventricular; % LVSW loss, percentage left ventricular stroke work loss index; ΔP_{mean} , mean transvalvular pressure gradient; Q_{mean} , mean transvalvular flow rate. Values in parentheses are the SD.

min; however, the infusion protocol did not have to be discontinued.

Table 2 shows the haemodynamics at baseline, peak BP intervention and recovery. From baseline to peak intervention, SBP increased by 27% ($p < 0.001$) and mean BP increased by 22% ($p < 0.001$). All patients demonstrated an increase in SBP and mean BP (fig 1). The increase in BP was similar in the handgrip and phenylephrine intervention cohorts (Δ mean (SD) BP 21 (10) vs 26 (6) mm Hg; $p = 0.22$). SVR increased by 20% ($p < 0.001$) and SAC decreased by 30% ($p < 0.001$). There was no significant change in stroke volume from baseline to intervention, although Q_{mean} decreased by 5% ($p = 0.02$; fig 1). The change in Q_{mean} was similar in the handgrip and phenylephrine cohorts (-19 (31) vs -6 (38) ml/s; $p = 0.54$). LV EF did not change from baseline to intervention (73 (8) vs 72 (9)%; $p = \text{NS}$).

Effect of change in blood pressure on indices of AS severity

Table 2 shows the indices of AS severity at baseline, peak BP intervention and recovery, and fig 2 shows the individual changes in Q_{mean} , ΔP_{mean} and AVA. There was no change in ΔP_{mean} from baseline to intervention (fig 3). In contrast, AVA decreased from 1.15 (0.32) to 1.09 (0.32) cm^2 ($p = 0.02$; fig 3). In all, 14 of the 22 patients demonstrated a decrease in AVA with the increase in BP (fig 4). The change in AVA from baseline to peak BP intervention ranged from -0.26 to $+0.11$ cm^2 . Notably, 5 of the 22 (23%) patients had a change in AVA that crossed a threshold of 1.5 or 1.0 cm^2 , thus changing the classification of AS severity according to the American College of Cardiology/American Heart Association Task Force on Practice guidelines.¹ The valve stenosis appeared more severe in four patients (two patients changed from mild to moderate AS; two patients changed from moderate to severe AS) and less severe in one patient (severe to moderate AS). The change in AVA with the BP intervention was not related to baseline AS severity ($r = -0.06$; $p = \text{NS}$).

SBP and mean BP were found to be lower at recovery than baseline, although Q_{mean} was similar. There was no difference between the average ΔP_{mean} and AVA at baseline and recovery in the study cohort. However, for individual patients, the change in AVA at either peak BP intervention or recovery ranged from -0.26 to $+0.26$ cm^2 of the baseline AVA.

Valve resistance, ELCo and % LVSW loss were also affected by the BP intervention (fig 5). From baseline to peak BP intervention, valve resistance increased ($p = 0.02$) and ELCo decreased ($p = 0.04$), giving the appearance that the valve

stenosis was more severe at a higher BP. In all, 15 of the 22 patients had an increase in valve resistance and 14 patients had a decrease in ELCo. In contrast, the valve stenosis appeared less severe at a higher BP when assessed by % LVSW loss ($p < 0.001$). Of the 22 patients, 21 had a decrease in % LVSW loss with the BP intervention. There was no difference between baseline and recovery valve resistance, ELCo or % LVSW loss.

Handgrip and phenylephrine infusion interventions resulted in similar changes in the indices of AS severity.

Relationship between the change in indices of AS severity, BP and transvalvular flow rate

The relationship between the change in mean BP and the change in AVA was examined by plotting the change from baseline to intervention and from baseline to recovery ($n = 44$). The change in AVA had an inverse linear relationship with the change in mean BP ($r = -0.34$; $p = 0.026$; fig 6). Similar inverse relationships were observed for the change in AVA and the change in SBP or SVR (table 3). The change in AVA had a direct linear relationship with the change in SAC. Importantly, there was a strong linear relationship between the change in AVA and the change in Q_{mean} ($r = 0.81$; $p < 0.001$; fig 6). Only the change in Q_{mean} was an independent predictor of the change in AVA (table 3). The change in BP, SVR and SAC had no independent effect on the change in AVA.

The change in Q_{mean} was also the only independent predictor of the change in valve resistance and ELCo. In contrast, change in Q_{mean} did not predict the change in % LVSW loss. The change in SBP and change in SAC were independent predictors of the change in % LVSW loss. No haemodynamic variable predicted the change in ΔP_{mean} , although the change in ΔP_{mean} was inversely related to the change in AVA ($r = -0.43$, $p = 0.004$).

DISCUSSION

The management of patients with AS requires an evaluation of the symptomatic status and an accurate measurement of the severity of valve stenosis.^{1,2} The latter is required to verify that the degree of valve stenosis is severe enough to account for a patient's symptoms. In addition, serial assessment of AS severity may identify patients at increased risk for the development of symptoms or an adverse event.³⁹⁻⁴¹ However, the BP may differ between serial assessments, yet the impact of a difference in BP on the assessment of AS severity has received little study, with conflicting results.²⁸⁻³⁰

In this study, handgrip exercise and phenylephrine infusion resulted in a significant increase in BP and SVR, with minimal effect on heart rate, ventricular dimensions or EF. ΔP_{mean}




Figure 1 Distribution of mean blood pressure (BP, panel A) and mean transvalvular flow rate (Q_{mean} , panel B) at baseline, peak BP intervention and recovery in the 22 patients.

Table 2 Comparison of haemodynamic data at baseline, intervention and recovery in the total cohort (n=22)

Variable	Baseline	Intervention	Recovery
Haemodynamic variables			
Heart rate (bpm)	62 (8)	67 (12)*	62 (13)
Systolic BP (mm Hg)	143 (14)	181 (20)†	136 (15)*
Diastolic BP (mm Hg)	77 (9)	92 (8)†	75 (8)
Mean BP (mm Hg)	99 (8)	121 (10)†	96 (7)*
Stroke volume (ml)	104 (19)	100 (22)	103 (19)
Q _{mean} (ml/s)	323 (67)	306 (66)*	324 (65)
Cardiac output (l/min)	6.34 (1.31)	6.55 (1.51)	6.16 (1.22)
SAC (ml/mm Hg)	1.66 (0.47)	1.16 (0.31)†	1.82 (0.60)*
SVR (dyne×s/cm ⁵)	1294 (264)	1552 (372)†	1280 (233)
Stenotic indices			
ΔP _{mean} (mm Hg)	36 (13)	36 (14)	35 (14)
AVA (cm ²)	1.15 (0.32)	1.09 (0.33)*	1.17 (0.33)
Resistance (dyne×s/cm ⁵)	153 (63)	164 (74)*	146 (62)
% LVSW loss (%)	19.8 (6.3)	16.5 (5.7)†	20.0 (7.1)
ELCo (cm ²)	1.32 (0.40)	1.24 (0.42)*	1.34 (0.43)
Change from baseline			
Q _{mean} (ml/s)		-17 (31)	1 (31)
ΔP _{mean} (mm Hg)		0 (3)	-1 (3)
AVA (cm ²)		-0.06 (0.11)	0.02 (0.11)
Resistance (dyne×s/cm ⁵)		11 (21)	-7 (26)
% LVSW loss (%)		-3.3 (1.7)	0.2 (2.3)
ELCo (cm ²)		-0.08 (0.17)	0.02 (0.16)

AVA, aortic valve area; BP, blood pressure; ELCo, energy loss coefficient; % LVSW loss, percentage left ventricular stroke work loss index; ΔP_{mean}, mean transvalvular pressure gradient; Q_{mean}, mean transvalvular flow rate; SAC, systemic arterial compliance; SVR, systemic vascular resistance.

Values in parentheses are the SD.

*p<0.05 vs baseline.

†p<0.001 vs baseline.

remained constant, despite the increase in BP. Presumably, LV systolic pressure increased in parallel with the acute augmentation of arterial pressure. In contrast, AVA decreased, resulting in the valve stenosis appearing more severe. Similarly, the valve stenosis appeared more severe when assessed using valve resistance or ELCo. In contrast, the valve stenosis appeared less severe when assessed using % LVSW loss.

Previous studies investigating the effect of BP and SVR on the measurement of AS severity have been contradictory.^{28–30} Transvalvular pressure gradient increased with increasing systolic pressure and SVR in an in vitro model using an aortic bioprosthesis and constant transvalvular flow rate.³⁰ In contrast, other investigators have suggested that the change in transvalvular pressure gradient is inversely related to the change in SVR,^{28–29–42} irrespective of flow.²⁸ However, the equation²⁸ predicting a “flow-independent” decrease in transvalvular pressure gradient as a consequence of increased SVR contains both

pressure and resistance variables that are inter-related by flow, and are thus not truly flow independent.^{29–30} We observed no change in ΔP_{mean} during the acute increase in BP and SVR, despite a small decrease in transvalvular flow. The failure of ΔP_{mean} to decrease despite reduced transvalvular flow was because of a small decrease in AVA. Decreased transvalvular flow results in reduced valve-opening forces and a smaller AVA, and, since ΔP_{mean} ∝ (Q_{mean}/AVA)², a smaller AVA would attenuate the expected decrease in ΔP_{mean} as a result of reduced Q_{mean}.^{5–6–9} Our in vivo observations are consistent with those in an animal model of supravalvular AS, in which ΔP_{max} and ΔP_{mean} were dependent only on the stenosis area and transvalvular flow, and not dependent on SVR or SAC.²⁹ Non-simultaneous peak LV pressure to peak aortic pressure differences derived at catheterisation may be affected by arterial compliance independent of transvalvular flow²⁹; however, this pressure difference cannot be measured using Doppler-echo.




Figure 2 Individual changes in mean transvalvular flow rate (Q_{mean}, panel A), mean transvalvular pressure gradient (ΔP_{mean}, panel B) and aortic valve area (AVA, panel C) at baseline, peak blood pressure intervention and recovery in the 22 patients.




Figure 3 Distribution of mean transvalvular pressure gradient (ΔP_{mean} , panel A) and aortic valve area (AVA, panel B) at baseline, peak blood pressure intervention and recovery in the 22 patients.

In an *in vitro* model with a constant transvalvular flow rate, AVA derived by the Gorlin equation decreased with increasing systemic pressure and SVR.³⁰ In contrast, both the Gorlin and continuity equation AVA increased when hypertension was induced in an animal model of supralvalvular AS.²⁹ In the current study, we observed a decrease in AVA with increased BP and SVR. The decrease in AVA probably occurred as a consequence of the concomitant decrease in transvalvular flow with the acute increase in BP. The change in Q_{mean} was the only independent predictor of the change in AVA. Change in BP, SVR and SAC had no independent effect on the change in AVA. Previous studies have demonstrated a strong linear relationship between AVA and Q_{mean} ,^{5,9} probably related to flow-mediated changes in the anatomic area of the valve stenosis or flow-mediated modification of the coefficient of orifice contraction.^{3,4,19,43-45} However, from our study, it is not possible to determine whether the mechanism of the observed change in AVA was primarily related to a change in the anatomic valve area, coefficient of orifice contraction, flow profiles within the

outflow tract or vena contracta, or a combination of these phenomena. The discrepancy between the observed decrease in AVA with an increase in BP, and the observed increase in AVA in an animal model of supralvalvular AS can probably be explained by expansion of the supralvalvular stenosis due to increased radial pressure, which does not occur with valvular stenoses.²⁹ Importantly, the change in trans-stenotic flow rate in this animal model was an independent predictor of the change in stenosis area, consistent with our observation.²⁹

Valve resistance, ELCo and % LVSW loss were also affected by the change in BP. Acute increase in BP and SVR resulted in the valve stenosis appearing more severe when assessed by valve resistance and ELCo. The change in Q_{mean} was the only independent predictor of the change in valve resistance and ELCo, similar to AVA. In contrast, the acute increase in BP resulted in the valve stenosis appearing less severe when assessed by % LVSW loss. Not surprisingly, the change in SBP was inversely related to the change in % LVSW loss, since SBP is in the denominator of the % LVSW loss equation. Larger reductions in transvalvular flow as a consequence of acute increase in BP could potentially lead to greater reductions in % LVSW loss, since transvalvular pressure gradient, incorporated in the numerator of the % LVSW loss equation, has a strong relationship with transvalvular flow.^{5-7,9} Clearly, none of these alternative stenotic indices can be relied upon to provide a constant measure of AS severity during a change in BP or transvalvular flow; however, the impact on the assessment and interpretation of AS severity will depend on the specific stenotic index used.

Clinical implications

In patients with AS, we observed that (1) acute hypertension can affect Doppler-echo indices of AS severity, and that (2) the change in AS severity with a change in BP is a consequence of concomitant changes in transvalvular flow, rather than an independent effect of systemic arterial haemodynamics (ie, SVR or SAC). The observation that the indices of AS severity are affected by changes in BP has important implications for the haemodynamic assessment of patients with AS with hypertension and patients undergoing serial evaluation of disease severity. Haemodynamics including BP and transvalvular flow should be recorded as part of each evaluation, and differences in haemodynamics considered as a potential explanation for a change in AS severity independent of disease progression. Although the change in average AVA with the acute increase in BP and SVR was small (1.15 to 1.09 cm²), the individual




Figure 4 Change in aortic valve area (AVA) from baseline to peak blood pressure intervention in the 22 patients. *Identifies patients in whom there was a change in the classification of aortic stenosis (AS) severity.




Figure 5 Distribution of valve resistance (panel A), energy loss coefficient (ELCo, panel B) and percentage left ventricular stroke work loss (% LVSW loss, panel C) at baseline, peak blood pressure intervention and recovery in the 22 patients.

patient response was variable (-0.26 to $+0.11$ cm^2 of baseline AVA). In all, 5 (23%) patients had a change in AVA resulting in a reclassification of AS severity according to American College of Cardiology/American Heart Association Task Force on Practice guidelines.¹ Even greater changes in AVA (-0.26 to $+0.26$ cm^2 of baseline AVA) were found when analysing in both the intervention and recovery periods, when the BP was lower (fig 6). Although the presence of symptoms is the major determinant for surgical intervention, the magnitude to which AVA can change in a patient (ie, 0.9 vs 1.15 cm^2) can clearly affect clinical decision making, especially in “grey” areas, where the symptom status of a patient may be unclear, or when evaluating the need for concomitant valve replacement in patients with milder degrees of AS undergoing coronary artery bypass graft surgery. Furthermore, the observed change in AVA is of a magnitude similar to the expected annual rate of haemodynamic progression (≈ 0.1 cm^2/year). Thus, a patient could be diagnosed as a “rapid progressor” as a result of different haemodynamics at the time of the assessment rather than actual disease progression.³⁹ Importantly, greater BP and associated transvalvular flow changes could result in greater perturbations in AVA, due to the linear relationship between these haemodynamic variables and AVA. Repeating the Doppler echocardiographic evaluation in patients with hypertension after normalisation of the BP may provide measurements that better reflect the severity of the valve stenosis and better identify actual disease progression during the follow-up studies.²

Potential limitations

We used models of acute increase in BP due to increased SVR to investigate the impact of BP on the assessment of AS severity. These models were not chosen for their ability to “mimic” the diverse pathophysiologies of hypertension. Rather, they were employed for their ability to affect predominantly BP and SVR, with little confounding effect on heart rate and transvalvular flow. Although these models may reflect the haemodynamics and define the expected impact of BP on the assessment of AS severity in clinical settings associated with an acute increase in BP due to increased SVR (ie, anxious patient undergoing catheterisation), they may not reflect the haemodynamics and impact of a change in BP in patients with a gradual BP increase or chronic hypertension. Chronic hypertension can be associated with either increased or decreased cardiac output, depending on the specific aetiology and time course within the disease.⁴⁶ In these chronic settings, the impact of BP on the assessment of AS severity may differ, depending on whether there is an associated increase or decrease in transvalvular flow. Ultimately, the concomitant change in transvalvular flow that occurs with a change in BP will determine the effect on the Doppler-echo assessment of AS severity, with the stenosis appearing more severe if there is a decrease in transvalvular flow, and less severe if there is an increase in transvalvular flow.

CONCLUSION

Doppler-echo assessment of AS severity is dependent on the systemic BP at the time of haemodynamic assessment. Acute




Figure 6 Scatter plot of the relationship between the change in aortic valve area (AVA) and the change in mean blood pressure (BP, panel A) and change in mean transvalvular flow rate (Q_{mean} , panel B) in the 22 patients.

Table 3 Univariate and multivariate analysis of the haemodynamic variables in which variation predicts a change in the index of aortic stenosis severity

AS severity index	Haemodynamic variable	Univariate r (p value)
ΔP_{mean} AVA	Δ AVA	-0.42 (0.004)*
	Δ Mean BP	-0.34 (0.026)
Resistance % LVSW loss	Δ Systolic BP	-0.32 (0.033)
	Δ SVR	-0.28 (0.061)
	Δ SAC	0.38 (0.011)
	Δ Q_{mean}	0.81 (<0.001)*
	Δ Q_{mean}	-0.73 (<0.001)*
	Δ Heart rate	-0.31 (0.044)
ELCo	Δ Mean BP	-0.78 (<0.001)*
	Δ Systolic BP	-0.82 (<0.001)*
	Δ SVR	-0.54 (<0.001)*
	Δ SAC	0.84 (<0.001)*
	Δ Mean BP	-0.36 (0.018)
	Δ Systolic BP	-0.32 (0.036)
	Δ SVR	-0.30 (0.045)
	Δ SAC	0.31 (0.038)
	Δ Q_{mean}	0.71 (<0.001)*

AS, aortic stenosis; AVA, aortic valve area; BP, blood pressure; ELCo, energy loss coefficient; % LVSW loss, percentage left ventricular stroke work loss index; ΔP_{mean} , mean transvalvular pressure gradient; Q_{mean} , mean transvalvular flow rate; SAC, systemic arterial compliance; SVR, systemic vascular resistance.

* $p < 0.01$ on multivariate analysis.

hypertension due to increased SVR and associated with a decrease in transvalvular flow can lead to a valve stenosis appearing more severe when assessed by AVA, valve resistance or ELCo, and less severe when assessed by % LVSW loss. However, the impact of BP on the assessment of AS severity depends primarily on the associated change in transvalvular flow rather than on the systemic arterial haemodynamics, and can lead to a stenosis appearing either more or less severe depending on the direction and magnitude of the change in transvalvular flow.

Authors' affiliations

Stephen H Little, Kwan-Leung Chan, Ian G Burwash, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Competing interests: None declared.

REFERENCES

- Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease). *J Am Coll Cardiol* 2006;**48**:e1-148.
- Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. *J Am Coll Cardiol* 2006;**47**:2141-51.
- Montarello JK, Perakis AC, Rosenthal E, et al. Normal and stenotic human aortic valve opening: in vitro assessment of orifice area changes with flow. *Eur Heart J* 1990;**11**:484-91.
- Chambers JB, Sprigings DC, Cochrane T, et al. Continuity equation and Gorlin formula compared with directly observed orifice area in native and prosthetic aortic valves. *Br Heart J* 1992;**67**:193-9.
- Burwash IG, Thomas DT, Sahadiro M, et al. Dependence of Gorlin formula and continuity equation valve areas on transvalvular volume flow rate in valvular aortic stenosis. *Circulation* 1994;**89**:827-35.
- Burwash IG, Pearlman AS, Kraft CD, et al. Flow dependence of measures of aortic stenosis severity during exercise. *J Am Coll Cardiol* 1994;**24**:1342-50.
- Bermejo J, Fernandez-Garcia MA, Torrecilla EG, et al. Effects of dobutamine on Doppler echocardiographic indexes of aortic stenosis. *J Am Coll Cardiol* 1996;**28**:1206-13.
- Shively BK, Charlton GA, Crawford MH, et al. Flow dependence of valve area in aortic stenosis: relation to valve morphology. *J Am Coll Cardiol* 1998;**31**:654-60.
- Burwash IG, Hay KM, Chan KL. Hemodynamic stability of valve area, valve resistance, and stroke work loss in aortic stenosis: a comparative analysis. *J Am Soc Echocardiogr* 2002;**15**:814-22.

- Beauchesne LM, deKemp R, Chan KL, et al. Temporal variations in effective orifice area during ejection in patients with valvular aortic stenosis. *J Am Soc Echocardiogr* 2003;**16**:958-64.
- Ford LE, Feldman T, Chiu C, et al. Hemodynamic resistance as a measure of functional impairment in aortic valvular stenosis. *Circ Res* 1990;**66**:1-7.
- Casale PN, Palacios IF, Abascal VM, et al. Effects of dobutamine on Gorlin and continuity equation valve areas and valve resistance in valvular aortic stenosis. *Am J Cardiol* 1992;**70**:1175-9.
- Martin TW, Moody JM, Bird JJ, et al. Effect of exercise on indices of valvular aortic stenosis. *Cathet Cardiovasc Diagn* 1992;**25**:265-71.
- Ford LE, Feldman T, Carroll JD. Valve resistance. *Circulation* 1994;**89**:893-5.
- Lee TM, Su SF, Chen MF, et al. Effects of increasing flow rate on aortic stenotic indices: evidence from percutaneous transvenous balloon dilatation of the mitral valve in patients with combined aortic and mitral stenosis. *Heart* 1996;**76**:490-4.
- Blitz LR, Herrmann HC. Hemodynamic assessment of patients with low-flow, low-gradient valvular aortic stenosis. *Am J Cardiol* 1996;**78**:657-61.
- Antonini-Canterin F, Faggiano P, Zanuttini D. Is aortic valve resistance more clinically meaningful than valve area in aortic stenosis? *Heart* 1999;**82**:9-10.
- Tobin JR, Rahimtoola SH, Blundell PE, et al. Percentage of left ventricular stroke work loss: a simple hemodynamic concept for estimation of severity in valvular aortic stenosis. *Circulation* 1967;**35**:868-79.
- Sprigings DC, Chambers JB, Cochrane T, et al. Ventricular stroke work loss: validation of a method of quantifying the severity of aortic stenosis and derivation of an orifice formula. *J Am Coll Cardiol* 1990;**16**:1608-14.
- Bermejo J, Odreman R, Feijoo J, et al. Clinical efficacy of Doppler-echocardiographic indices of aortic valve stenosis: a comparative test-based analysis of outcome. *J Am Coll Cardiol* 2003;**41**:142-51.
- Garcia D, Pibarot P, Dumesnil JG, et al. Assessment of aortic valve stenosis severity: a new index based on the energy loss concept. *Circulation* 2000;**101**:765-71.
- Das P, Pocock C, Chambers J. The patient with a systolic murmur: severe aortic stenosis may be missed during cardiovascular examination. *QJM* 2000;**93**:685-8.
- Lindroos M, Kupari M, Valvanne J, et al. Factors associated with calcific aortic valve degeneration in the elderly. *Eur Heart J* 1994;**15**:865-70.
- le E, Mook W, Shapiro AP. Systolic hypertension in critical aortic stenosis and the effect of valve replacement. *J Hum Hypertens* 1996;**10**:65-7.
- Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. *J Am Coll Cardiol* 1997;**29**:630-4.
- Chan KL, Ghani M, Woodend K, et al. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. *Am J Cardiol* 2001;**88**:690-3.
- Antonini-Canterin F, Huang G, Cervasato E, et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role? *Hypertension* 2003;**41**:1268-72.
- Laskey W, Kussmaul W, Noordergraaf A. Valvular and systemic arterial hemodynamics in aortic valve stenosis: model-based approach. *Circulation* 1995;**92**:1473-8.
- Kadem I, Dumesnil JG, Rieu R, et al. Impact of systemic hypertension on the assessment of aortic stenosis. *Heart* 2005;**91**:354-61.
- Razzolini R, Gerosa G, Leoni L, et al. Transaortic gradient is pressure-dependent in a pulsatile model of the circulation. *J Heart Valve Dis* 1999;**8**:279-83.
- Bermejo J. The effects of hypertension on aortic valve stenosis. *Heart* 2005;**91**:280-2.
- Chambers J. Editorial: can high blood pressure mask severe aortic stenosis? *J Heart Valve Dis* 1998;**7**:277-8.
- White M, Fournay A, Etel M, et al. Effects of age and hypertension on cardiac responses to the α_1 -agonist phenylephrine in humans. *Am J Hypertens* 1999;**12**:151-8.
- Burwash IG, Forbes AD, Sadahiro M, et al. Echocardiographic volume flow and stenosis severity measures with changing volume flow rates in aortic stenosis. *Am J Physiol* 1993;**265**:H1734-43.
- Chemla D, Hébert J-L, Coirault C, et al. Total arterial compliance estimated by stroke volume-to-aortic pulse pressure ratio in humans. *Am J Physiol* 1998;**274**:H500-5.
- Zoghbi WA, Farmer KL, Soto JG, et al. Accurate noninvasive quantification of stenotic aortic valve area by Doppler echocardiography. *Circulation* 1986;**73**:452-9.
- Otto CM, Pearlman AS, Comess KA, et al. Determination of the stenotic aortic valve area in adults using Doppler echocardiography. *J Am Coll Cardiol* 1986;**7**:509-17.
- Ho PP, Pauls GL, Lamberton DF, et al. Doppler derived aortic valve resistance in aortic stenosis: its hemodynamic validation. *J Heart Valve Dis* 1994;**3**:283-7.
- Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. *Circulation* 1997;**95**:2262-70.
- Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. *N Engl J Med* 2000;**343**:611-17.
- Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. *Eur Heart J* 2004;**25**:199-205.
- Silove ED, Vogel JH, Grover RF. The pressure gradient in ventricular outflow obstruction: influence of peripheral resistance. *Cardiovasc Res* 1968;**2**:234-42.

- 43 **DeGroff CG**, Shandas R, Valdes-Cruz L. Analysis of the effect of flow rate on the Doppler continuity equation for stenotic orifice area calculations: a numerical study. *Circulation* 1998;**97**:1597–605.
- 44 **Segal J**, Lerner DJ, Miller C, *et al.* When should Doppler determined valve area be better than the Gorlin formula? Variation in hydraulic constants in low flow states. *J Am Coll Cardiol* 1987;**9**:1294–305.
- 45 **Voelker W**, Reul H, Nienhaus G, *et al.* Comparison of valvular resistance, stroke work loss, and Gorlin valve area for quantitation of aortic stenosis. An in vitro study in a pulsatile aortic flow model. *Circulation* 1995;**91**:1196–204.
- 46 **Kaplan NM**. Systemic hypertension: mechanism and diagnosis. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. *Braunwald's heart disease: a textbook of cardiovascular medicine*. 7th edn. Philadelphia, PA: Elsevier Saunders, 2005:959–87.

IMAGES IN CARDIOLOGY

doi: 10.1136/hrt.2006.095265

Endocarditis of left ventricular apical patch with cavity formation

An 82-year-old man was admitted for septic fever and chills in May 2005. He had undergone coronary artery bypass grafting and aneurysmectomy of the left ventricular apical aneurysm in September 2004. Since January 2005, he had complained about episodes of night sweating, fever with chills and fatigue. Antibiotics prescribed by the general physician had no effect.

Several separate sets of blood cultures done after admission were positive for *Staphylococcus epidermidis*, resistant to methicillin. Echocardiography showed poor two-dimensional image quality. Cardiac magnetic resonance revealed apical pseudoaneurysm (32×17×36 mm) overlying the implanted patch, with a small intermittent shunt between left ventricular and pseudoaneurysmal cavity (panel A). Nevertheless, another oval-shaped cavity (32×18×40 mm) was observed distally to the pseudoaneurysm (panel B). Both cavities were filled with blood clots. Yet, a small bidirectional blood flow was noted between both spaces (data supplement movie clip is available online at <http://heart.bmj.com/supplemental>). After intensive


antibiotic treatment, inflammatory markers and white blood cell count were normalised and blood cultures were repeatedly negative. After discharge, the patient did not show any signs of relapse at regular follow-ups.

Acknowledgements: All authors from the Cardiocenter were supported by the Charles University Prague Research Project MSM 0021620817 awarded by the Ministry of Education, Youth and Physical Education of the Czech Republic.

Karol Curila, Jaroslav Tintera, Martin Penicka
curila@fnkv.cz



Supplemental video is available on the *Heart* website at <http://heart.bmj.com/supplemental>



Panel A shows an irregular space between the apical patch and pericardium, which represents apical pseudoaneurysm (arrow). Apical pseudoaneurysm may develop after left ventricular aneurysmectomy and, usually, does not require any specific treatment. Panel B shows an oval-shaped cavity connected with pseudoaneurysm (arrow). This finding is clear pathology and may be related to *Staphylococcus* infection.

ME van der Elst substantially contributed to the design, analysis and interpretation of data, drafting the article and final approval of the version to be published. He will act as guarantor for the paper. ML Bouvy, CJ de Blaey and A de Boer substantially contributed to the design and interpretation of data, revising the article critically for important intellectual content and final approval of the version to be published.

REFERENCES

- 1 **Anonymous.** *Demographic Yearbook 1997*, English/French ed. New York: Publishing Division United Nations, 1998.
- 2 **AHA.** 2002 Heart and stroke statistical update. Dallas: American Heart Association, 2001. <http://www.americanheart.org> (accessed 27 October 2005).
- 3 **Statline.** Population, monthly and yearly data. Statistics Netherlands. <http://statline.cbs.nl> (accessed 27 October 2005).
- 4 **Antithrombotics trialist collaboration.** Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;**324**:71–86.
- 5 **Freemantle N, Cleland J, Young P, et al.** β Blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ* 1999;**318**:1730–7.
- 6 **Mehra RH, Eagle KA.** Secondary prevention in acute myocardial infarction. *BMJ* 1998;**316**:838–42.
- 7 **van der Elst ME, Buurma H, Bouvy ML, et al.** Drug therapy for prevention of recurrent myocardial infarction. *Ann Pharmacother* 2003;**37**:1465–77.
- 8 **Anand SS, Yusuf S.** Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. *JAMA* 1999;**282**:2058–67.
- 9 **Dagenais GR, Yusuf S, Bourassa MG, et al.** Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. *Circulation* 2001;**104**:522–6.
- 10 **Gottlieb SS, McCarter RJ, Vogel RA.** Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med* 1998;**339**:489–97.
- 11 **Goldbourt U, Behar S, Reicher-Reiss H, et al.** Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. *Arch Intern Med* 1993;**153**:345–53.
- 12 **Dargie HJ.** Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001;**357**:1385–90.
- 13 **Heart Protection Study Collaborative Group.** MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;**360**:7–22.
- 14 **Yusuf S, Sleight P, Pogue J, et al.** Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;**342**:145–53.
- 15 **van Bergen PF, Deckers JW, Jonker JJ, et al.** Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. *Br Heart J* 1995;**74**:117–21.
- 16 **Smith P, Arnesen H, Abdelnoor M.** Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction. *Arch Intern Med* 1992;**152**:993–7.
- 17 **Pyrala K, De Backer G, Graham I, et al.** Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. *Eur Heart J* 1994;**15**:1300–31.
- 18 **Smith SC Jr, Blair SN, Bonow RO, et al.** AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* 2001;**104**:1577–9.
- 19 **Wald NJ, Law MR.** A strategy to reduce cardiovascular disease by more than 80%. *BMJ* 2003;**326**:1419.
- 20 **Hippisley-Cox J, Coupland C.** Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. *BMJ* 2005;**330**:1059–63.
- 21 **Herings RM, Bakker A, Stricker BH, et al.** Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. *J Epidemiol Community Health* 1992;**46**:136–40.
- 22 **Institute for Drug Outcome Research.** The Pharmo Database. Pharmo Institute. <http://www.pharmo.nl> (accessed 27 October 2005).
- 23 **Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, et al.** Comparison of different methods to estimate prevalence of drug use by using pharmacy records. *J Clin Epidemiol* 2001;**54**:1181–6.
- 24 **Herings RM, de Boer A, Stricker BH, et al.** A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0–19 years of age. *Pharm World Sci* 1995;**17**:17–9.
- 25 **Maitland-van der Zee AH, Klungel OH, Stricker BH, et al.** Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study. *Pharm World Sci* 2003;**25**:70–2.
- 26 **Zhang J, Yu KF.** What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA* 1998;**280**:1690–1.
- 27 **Davies HT, Crombie IK, Tavakoli M.** When can odds ratios mislead? *BMJ* 1998;**316**:989–91.

WEB TOP 10

www.heartjnl.com

These articles scored the most hits on *Heart's* website during July 2007

1 JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice

December 2005;**91**(suppl V):1–52. (Supplement)

2 Treatment of stable angina

I Ben-Dor, A Battler

July 2007;**93**:868–74. (Education in Heart)

3 Pericardial disease: what the general cardiologist needs to know

EL Ivens, BI Munt, RR Moss

August 2007;**93**:993–1000. (Education in Heart)

4 Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials

J Afilalo, AA Majdan, MJ Eisenberg

August 2007;**93**:914–21. (Systematic review)

5 Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis

SH Little, K-L Chan, IG Burwash

July 2007;**93**:848–55. (Original research)

6 Management of end stage heart failure

EB Friedrich, M Böhm

May 2007;**93**:626–31. (Education in Heart)

7 Cardiovascular magnetic resonance in the evaluation of heart failure

RG Assomull, DJ Pennell, SK Prasad

August 2007;**93**:985–92. (Education in Heart)

8 Improving end-of-life care for patients with chronic heart failure: "Let's hope it'll get better, when I know in my heart of hearts it won't"

L Selman, R Harding, T Beynon, F Hodson, E Coady,

C Hazeldine, M Walton, L Gibbs, IJ Higginson

August 2007;**93**:963–7. (Original research)

9 Differential diagnosis of elevated troponins

S Korff, HA Katus, E Giannitsis

July 2006;**92**:987–93. (Education in Heart)

10 Drug induced QT prolongation and torsades de pointes

YG Yap, AJ Camm

November 2003;**89**:1363–72. (Education in Heart)

Visit the *Heart* website for hyperlinks to these articles, by clicking on "Top 10 papers"

www.heartjnl.com